{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Protein+Kinase+Inhibitors&page=2", "query": { "condition": "Protein Kinase Inhibitors", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Protein+Kinase+Inhibitors&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T04:54:04.683Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00504205", "title": "MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "multitargeted receptor tyrosine kinase inhibitor MP470", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "positron emission tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Astex Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2007-05", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-06-11T04:54:04.683Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • San Antonio, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00504205" }, { "nct_id": "NCT01479842", "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Splenic Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "BTK inhibitor PCI-32765", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bendamustine hydrochloride", "type": "DRUG" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Kami Maddocks, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2014-03-26", "completion_date": "2026-09-01", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-06-11T04:54:04.683Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01479842" }, { "nct_id": "NCT02328014", "title": "Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkins Lymphoma", "Multiple Myeloma", "B-All" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "ACP-319", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2014-12-20", "completion_date": "2025-10-30", "has_results": true, "last_update_posted_date": "2025-12-09", "last_synced_at": "2026-06-11T04:54:04.683Z", "location_count": 7, "location_summary": "Orange, California • Bethesda, Maryland • Rochester, New York + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Rochester", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02328014" }, { "nct_id": "NCT01804686", "title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Mantle Cell Lymphoma", "Follicular Lymphoma", "Diffuse Large B-cell Lymphoma", "Waldenstrom Macroglobulinemia", "Chronic Graft Versus Host Disease" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2013-09-09", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-11T04:54:04.683Z", "location_count": 32, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 27 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01804686" }, { "nct_id": "NCT04458259", "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastasis" ], "interventions": [ { "name": "PF-07265807", "type": "DRUG" }, { "name": "Sasanlimab", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2020-09-24", "completion_date": "2024-11-15", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-11T04:54:04.683Z", "location_count": 25, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04458259" }, { "nct_id": "NCT01478581", "title": "Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "PCI-32765", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2012-03", "completion_date": "2018-08", "has_results": true, "last_update_posted_date": "2020-03-10", "last_synced_at": "2026-06-11T04:54:04.683Z", "location_count": 11, "location_summary": "La Jolla, California • Baltimore, Maryland • Boston, Massachusetts + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01478581" }, { "nct_id": "NCT06151730", "title": "Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Lymphocytic Leukemia", "Hematopoietic and Lymphoid System Neoplasm", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Non-Interventional Study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100, "start_date": "2024-01-05", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-06-11T04:54:04.683Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06151730" }, { "nct_id": "NCT00574366", "title": "Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "erlotinib", "type": "DRUG" }, { "name": "RAD001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2005-12", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2016-05-10", "last_synced_at": "2026-06-11T04:54:04.683Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00574366" }, { "nct_id": "NCT01865747", "title": "A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Cabozantinib tablets", "type": "DRUG" }, { "name": "Everolimus (Afinitor) tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 658, "start_date": "2013-06", "completion_date": "2021-01-15", "has_results": true, "last_update_posted_date": "2021-04-27", "last_synced_at": "2026-06-11T04:54:04.683Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01865747" }, { "nct_id": "NCT04305444", "title": "Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Richter's Transformation" ], "interventions": [ { "name": "DTRM-555", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zhejiang DTRM Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2020-04-24", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-06-11T04:54:04.683Z", "location_count": 8, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305444" } ] }